MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 893 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
(R)-STU104-d6
CAS:(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.Formula:C18H182D6O4Color and Shape:SolidMolecular weight:304.37ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01RSK4-IN-1
CAS:RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.Formula:C19H20F2N4O3Color and Shape:SolidMolecular weight:390.38HPK1-IN-3
HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.Formula:C23H22F4N6O2Color and Shape:SolidMolecular weight:490.45SOS1-IN-9
SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).Formula:C22H28F3N5OColor and Shape:SolidMolecular weight:435.49KRAS inhibitor-41
CAS:KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.Formula:C30H37FN10OSColor and Shape:SolidMolecular weight:604.745Casein kinase 1δ-IN-27
CAS:Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.Formula:C21H19FN6Color and Shape:SolidMolecular weight:374.414p38 MAP Kinase-IN-1
CAS:p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.Formula:C20H19FN6OColor and Shape:SolidMolecular weight:378.403p38 Kinase inhibitor 7
CAS:p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.Formula:C22H25FN6OColor and Shape:SolidMolecular weight:408.472p38α inhibitor 8
CAS:p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.Formula:C17H13FN6Color and Shape:SolidMolecular weight:320.324KRAS G12C inhibitor 44
KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.Formula:C31H36ClFN6O2Color and Shape:SolidMolecular weight:579.11HPK1 ligand-Linker Conjugate 1
CAS:HPK1 ligand-Linker Conjugate 1 is a synthetic target protein ligand-linker compound used in the synthesis of PROTACs, such as PROTACHPK1 Degrader-5. PROTACHPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity.Formula:C19H21N3O7SColor and Shape:SolidMolecular weight:435.45p38 Kinase inhibitor 8
CAS:p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.Formula:C22H21FN6O2Color and Shape:SolidMolecular weight:420.44SOS1 activator 2
CAS:SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.Formula:C26H28ClFN6Color and Shape:SolidMolecular weight:478.992Rho GTPase inhibitor 1
CAS:Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.Formula:C18H16N2OColor and Shape:SolidMolecular weight:276.33MEK4 inhibitor-2
CAS:MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.Formula:C20H15FN4O3SColor and Shape:SolidMolecular weight:410.42EBI-907
CAS:EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.Formula:C23H21ClF2N4O3SColor and Shape:SolidMolecular weight:506.95Fulzerasib
CAS:Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutantFormula:C32H30ClFN6O4Purity:98.04%Color and Shape:SolidMolecular weight:617.07SOS1-IN-6
CAS:SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).Formula:C26H28F3N3O2Color and Shape:SolidMolecular weight:471.51HPK1-IN-21
HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.Formula:C22H25ClFN5O2Color and Shape:SolidMolecular weight:445.92XMU-MP-9
CAS:XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.Formula:C19H13ClFN3OSColor and Shape:SolidMolecular weight:385.84pan-Raf/RTK inhibitor 1
CAS:Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.Formula:C29H28F3N7O3Color and Shape:SolidMolecular weight:579.573JNK-1-IN-5
CAS:JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.Formula:C23H21BrN6O3Color and Shape:SolidMolecular weight:509.355MEK1/2-IN-2
MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.Formula:C28H22ClFN6OColor and Shape:SolidMolecular weight:512.97KRAS inhibitor-27
CAS:KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106HPK1-IN-16
CAS:HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.Formula:C28H27FN4OColor and Shape:SolidMolecular weight:454.54JD118
CAS:JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).
Formula:C13H12N4S2Color and Shape:SolidMolecular weight:288.391HPK1-IN-31
HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63JH295 hydrate
JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.Formula:C18H18N4O3Color and Shape:SolidMolecular weight:338.36AMG-548 dihydrochloride
AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.Formula:C29H29Cl2N5OColor and Shape:SolidMolecular weight:534.48ERK2 IN-1
CAS:ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.Formula:C36H34FN7O2SPurity:98%Color and Shape:SolidMolecular weight:647.76HPK1-IN-30
CAS:HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.Formula:C25H23FN6Color and Shape:SolidMolecular weight:426.49ATX inhibitor 26
CAS:ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30p38α-MK2-IN-1
CAS:p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.Formula:C27H26F3N5O3Color and Shape:SolidMolecular weight:525.522COTI-219
CAS:COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43Calderasib
CAS:Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitorsFormula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08PAT-IN-1
CAS:PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05KRAS ligand 3
CAS:KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51KRAS inhibitor-31
CAS:KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62KRAS G12D inhibitor 19
CAS:KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68SML-10-70-1
CAS:SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.Formula:C25H42ClN7O13P2Color and Shape:SolidMolecular weight:746.04HPK1-IN-42
CAS:HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].Formula:C26H30N6OSColor and Shape:SolidMolecular weight:474.62MBA-m1
CAS:MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.Formula:C27H21ClN2O2Color and Shape:SolidMolecular weight:440.92NHTD
CAS:NHTD, a KRAS-PDEδ inhibitor, exerts its function by targeting the isoprenyl binding pocket of PDEδ, which alters the cellular localization of KRAS. This modification restricts the proliferation of cancer cells with KRAS mutations and induces cell apoptosis (Apoptosis). NHTD is utilized in the study of KRAS-driven non-small cell lung cancer (NSCLC).Formula:C24H26N2O5Color and Shape:SolidMolecular weight:422.47G-479
CAS:G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.Formula:C16H15FIN5O4Color and Shape:SolidMolecular weight:487.22(+)-Perillyl alcohol
CAS:(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.Formula:C10H16OColor and Shape:SolidMolecular weight:152.23HPK1-IN-41
CAS:HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].Formula:C28H33N5O2Color and Shape:SolidMolecular weight:471.59TH-Z816
CAS:TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].Formula:C29H38N6OColor and Shape:SolidMolecular weight:486.65Famlasertib
CAS:Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.Formula:C26H27ClN4OColor and Shape:SolidMolecular weight:446.972KRAS G12D inhibitor 12
KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)Formula:C23H21ClFN5O3Color and Shape:SolidMolecular weight:469.9
